<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03584464</url>
  </required_header>
  <id_info>
    <org_study_id>V 4.0 16Feb2018</org_study_id>
    <nct_id>NCT03584464</nct_id>
  </id_info>
  <brief_title>RESOLUTE ONYX Post-Approval Study (Bifurcation Cohort)</brief_title>
  <official_title>A Post-approval Study of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Vascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe the continued performance of the Medtronic Resolute Onyx™ Zotarolimus-Eluting
      Coronary Stent System in a real-world more-comer population.

      To collect data on the safety and efficacy of the Medtronic Resolute Onyx™
      Zotarolimus-Eluting Coronary Stent System in bifurcated lesions.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 14, 2018</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Target Vessel Failure (TVF) at 12 months post procedure</measure>
    <time_frame>12 Months</time_frame>
    <description>Target Lesion Failure (TVF) defined as cardiac death, target vessel myocardial infarction, or clinically-driven target vessel revascularization by percutaneous or surgical methods.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Acute Success (Device, Lesion, Procedure) at hospital discharge, 30 days and 6, 12, 24, and 36 months post-procedure</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Acute Success (Device, Lesion, Procedure) defined as attainment of &lt; 50% residual stenosis of the target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Cardiac Death at hospital discharge, 30 days and 6, 12, 24, and 36 months post-procedure</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Cardiac Death defined as any death due to immediate cardiac cause, unwitnessed death and death of unknown cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Target Vessel Myocardial Infarction (TVMI) at hospital discharge, 30 days and 6, 12, 24, and 36 months post-procedure</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Target Vessel Myocardial Infarction (TVMI) defined as myocardial infarction with the target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Target Lesion Revascularization (TLR) at hospital discharge, 30 days and 6, 12, 24, and 36 months post-procedure</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Target Lesion Revascularization (TLR) defined as repeat PCI, CABG to the target lesion, or clinically driven target lesion revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Target Vessel Revascularization (TVR) at hospital discharge, 30 days and 6, 12, 24, and 36 months post-procedure</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Target Vessel Revascularization (TVR) defined as revascularization of the target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Cardiac Death and TVMI at hospital discharge, 30 days and 6, 12, 24, and 36 months post-procedure</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Cardiac Death and TVMI defined as composite of cardiac death and target vessel myocardial infarction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Major Adverse Cardiac Event (MACE) at hospital discharge, 30 days and 6, 12, 24, and 36 months post-procedure</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Major Adverse Cardiac Event (MACE) defined as death, myocardial infarction (Q wave and non-Q wave), emergent coronary bypass surgery, or clinically driven repeat target lesion revascularization by percutaneous or surgical methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Target Lesion Failure (TLF) at hospital discharge, 30 days and 6, 12, 24, and 36 months post-procedure</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Target Lesion Failure (TLF) defined as cardiac death, target vessel myocardial infarction (Q wave and non-Q wave), or clinically driven target lesion revascularization (TLR) by percutaneous or surgical methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Target Vessel Failure (TVF) at hospital discharge, 30 days and 6, 12, 24, and 36 months post-procedure</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Target Vessel Failure (TVF) defined as cardiac death, target vessel myocardial infarction, or clinically-driven target vessel revascularization by percutaneous or surgical methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Stent Thrombosis (ST) at hospital discharge, 30 days and 6, 12, 24, and 36 months post-procedure</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Stent Thrombosis (ST) defined per Academic Research Consortium (ARC).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">205</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Bifurcation Cohort</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects receiving stents 2.0 mm - 5.0 mm in diameter will be included in the Bifurcation Cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System</intervention_name>
    <description>Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 2.0 mm - 4.0 mm</description>
    <arm_group_label>Bifurcation Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria

          -  Symptomatic coronary artery disease including subjects with chronic stable angina,
             silent ischemia, and acute coronary syndromes including non-ST elevation and
             ST-elevation myocardial infarction

          -  Subject is an acceptable candidate for treatment with a drug eluting stent in
             accordance with the applicable guidelines on percutaneous coronary interventions,
             manufacturer's Instructions for Use, and the Declaration of Helsinki

          -  Subject requires treatment of a single de novo bifurcated lesion amenable to treatment
             with Resolute Onyx using the provisional stenting technique

        Exclusion Criteria:

          -  Unprotected left main disease

          -  Subjects with planned PCI of three vessel disease

          -  Planned two stent technique (main branch and side branch) of a bifurcation

          -  Subjects with more than one bifurcation lesion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Scripps Green Hospital</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morton Plant Hospital</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centennial Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 14, 2018</study_first_submitted>
  <study_first_submitted_qc>June 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2018</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

